ROCKET PHARMACEUTICALS, INC.

Rocket Pharmaceuticals (RCKTW) showed no detected cyber incidents or red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability in the near term. However, a 90-day absence of signals does not eliminate underlying risks—particularly for a clinical-stage biotech where dilution, financing runway, and capital structure dynamics drive shareholder value. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk scores, maps financing history and burn rate, and flags AI-detected signals across 8-K language and officer activity. The full $49 Report adds those structural risk layers and provides the capital-structure context necessary for informed position sizing.